Coexistence of cerebral hypometabolism and neuroinflammation in the thalamo-limbic-brainstem region in young women with functional somatic syndrome

Takashi Matsudaira 1,2, Tatsuhiro Terada 1,2, Tomokazu Obi 2, Masamichi Yokokura 3, Yukitoshi Takahashi 4 and Yasuomi Ouchi 1*

Abstract

Background: Functional somatic syndrome (FSS) is a disorder characterized by clusters of medically unexplained symptoms. Some women suffer from persistent FSS after human papillomavirus (HPV) vaccination. However, a causal relationship has not been established, and the pathophysiology of FSS remains elusive. Here, we aimed to identify the brain regions showing altered cerebral metabolism and neuroinflammation in patients with FSS and to correlate the measures of positron emission tomography (PET) with clinical data. Twelve women diagnosed with FSS following HPV vaccination (FSS group) underwent both [18F]FDG-PET to measure glucose metabolism and [11C]DPA713-PET to measure neuroinflammation. [18F]FDG standardized uptake value ratio (SUVR) and [11C]DPA713 binding potential (BP ND) values were compared voxel-wise between the FSS and control groups (n = 12 for [18F]FDG, n = 16 for [11C]DPA713). A region-of-interest (ROI)-based analysis was performed to correlate PET parameters with clinical scores. Statistical significance was set at p < 0.05 corrected for multiple comparisons.

Results: Statistical parametric mapping revealed a concomitant significant decrease of [18F]FDG SUVR and increase of [11C]DPA713 BP ND in the regions covering the thalamus, mesial temporal area, and brainstem in the FSS group. Correlation analysis revealed that intelligence and memory scores were significantly positively correlated with [18F]FDG SUVR and negatively so with [11C]DPA713 BP ND in these regions. A direct comparison between [18F]FDG SUVR and [11C]DPA713 BP ND revealed a significant positive correlation in the right hippocampus and amygdala.

Conclusions: Cerebral hypometabolism with neuroinflammation occurring in the thalamo-limbic-brainstem region may reflect the pathophysiology of FSS.

Keywords: [11C]DPA713, [18F]FDG, Functional somatic syndrome, Glucose metabolism, Neuroinflammation, Positron emission tomography

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background
Functional somatic syndrome (FSS) is a disorder characterized by clusters of medically unexplained symptoms even after extensive examinations [1]. Most well-known FSS conditions are fibromyalgia, chronic fatigue syndrome (CFS), and irritable bowel syndrome, which often exhibit several common symptoms and share similar treatments [1, 2]. Recent studies from Japan and Denmark have reported that some women exhibit various long-lasting physical, psychological, cognitive, and behavioral symptoms following human papillomavirus (HPV) vaccination (a prophylactic measure against future development of cervical cancer) [3, 4]. In Japan, the post-vaccination symptoms have finally regarded as various somatic symptoms without the causal relationship with HPV vaccination [5]; however, the pathophysiology of FSS itself remains elusive.

FSS symptoms, such as widespread pain, psychiatric symptoms, and cognitive dysfunction, suggest a disturbance of the somatosensory system based on the thalamus, a relay region for almost all sensory information, and the limbic system, a part of the brain involved in memory, emotion, and the default-mode network [6]. Thus, we hypothesized that the etiology of FSS may be associated with the disruption of the brain milieu in these regions.

Positron emission tomography (PET) with $^{18}$F-FDG has been extensively used to detect cerebral glucose metabolic alterations, reflecting cerebral function (neuronal and synaptic activity) and/or cellular abnormalities [7]. Recent studies indicated that a disturbance of the brain milieu accompanies neuroinflammation [8, 9], which can be visualized by PET with radiotracers for the 18 kDa translocator protein (TSPO) developed in glial cells such as microglia and astrocytes [8, 10–12]. Among radiotracers for TSPO, $^{11}$C]DPA-713 is considered a second-generation ligand for the TSPO. Several studies on FSS implicated changes at the immunomolecular level, suggesting the involvement of neuroinflammation in the pathophysiology of FSS [13–15]. While previous PET studies revealed regional cerebral abnormalities in fibromyalgia and CFS [16–18], there are no pathophysiological studies on FSS regarding symptom-related brain regions with simultaneous cerebral glucose metabolism and neuroinflammation.

Therefore, we aimed to identify the brain regions showing altered cerebral metabolism and neuroinflammation in patients with FSS and to correlate the results of PET with clinical data to better understand the pathophysiology of FSS.

Material and methods
Participants
From February 2014 to February 2017, women who complained of symptoms of unknown cause after HPV vaccination were admitted to the Shizuoka Institute of Epilepsy and Neurological Disorders in Japan. The diagnosis of FSS was based on the various persistent somatic symptoms after HPV vaccination, which remained medically unexplained even after extensive medical assessment or overlapped with CFS and fibromyalgia [1]. The exclusion criteria were as follows: the presence of pathological findings on magnetic resonance imaging (MRI) unrelated to symptoms, a history of neurological and psychiatric disorders prior to FSS onset, and organic diagnosis during symptom development. After applying the exclusion criteria, 12 female patients with FSS were included in this study (FSS group; mean age ± standard deviation [SD] 19.3 ± 1.5 years). The FSS group underwent both $^{18}$F-FDG-PET to measure glucose metabolism and $^{11}$C]DPA-713 PET to measure neuroinflammation. A total of 28 healthy women were selected as controls; they had no neurological problems, history of serious illness, or psychiatric disorders. Of the 28 controls, 12 underwent $^{18}$F-FDG-PET (FDG control group; mean age 32.8 ± 9.5 years); the other 16 were age-matched and underwent $^{11}$C]DPA713-PET (DPA control group; mean age 20.6 ± 1.6 years).

The clinical scores for the FSS group were assessed using the following questionnaires: numerical rating scale for pain, Chalder fatigue scale, Stanford sleepiness scale, Wechsler Adult Intelligence Scale-Third Edition (WAIS-III), and Wechsler Memory Scale-Revised (WMS-R). The numerical rating scale for pain ranges from 0 (no pain) to 10 (worst pain) [19]. The Chalder fatigue scale consists of 11 questions, and the total score ranges from 0 to 33 [20], with higher scores indicating a greater degree of fatigue. The Stanford sleepiness scale evaluates sleepiness ranging from 1 (wide awake) to 7 (no longer fighting sleep) [21]. The WAIS-III and WMS-R evaluate cognitive ability, with mean IQ and memory scale defined as 100 and standard deviation as 15.

This study was reviewed and approved by the Ethics Committee of Hamamatsu PET Medical Photonics Center and the Shizuoka Institute of Epilepsy and Neurological Disorders. We obtained written informed consent from all patients or their guardians prior to PET scan.

MRI scanning
Prior to PET scanning, brain MRI (1.5-T GE, Signa Excite HDx, GE Medical Systems, Milwaukee, WI) was performed with three-dimensional mode sampling to determine the areas for setting region of interest (ROI), using the following acquisition parameters: repetition time = 25.0, echo time = minimum, flip angle 30°, slice thickness 1.5 mm, matrices 256 × 128, and field of view = 24.0. With reference to the measures of tilt angle and spatial coordinates obtained to determine the anterior commissure–posterior commissure (AC–PC) line on each participant’s sagittal MRI, a PET gantry was set as parallel to the AC–PC line by
tilting and moving the gantry for each study. The MRI measurements and mobile PET gantry allow us to reconstruct PET images parallel to the AC–PC line without reslicing.

**PET data acquisition**

All participants underwent a series of PET measurements after brain MRI scanning. We used a high-resolution brain PET scanner (SHR12000; Hamamatsu Photonics K.K., Hamamatsu, Japan). The gantry was set parallel to the AC–PC line determined by brain MRI. A thermoplastic face mask was used to fix the head to the same place during each PET scan. First, a 10-min transmission scan with a $^{68}$Ge/$^{68}$Ga source was performed for attenuation correction. Then, a PET measurement with $^{[11C]}$DPA713 was performed to investigate neuroinflammation on both the FSS and DPA control groups. In this measurement, serial emission scans were obtained for 90 min after a slow bolus venous injection (taking 1 min) of a 5 MBq/kg dose of $^{[11C]}$DPA713. Lastly, a static 15-min PET scan was done 45 min after injection of a 100-MBq dose of $^{[18F]}$FDG. The interval of these scans was 2.5 h after the cessation of the $^{[11C]}$DPA713 measurement. We recruited age-matched control female participants in the DPA control group for comparison because age is a key factor for neuroinflammation in the brain [22]. No arterial sampling was performed along with each PET measurement.

**Image data processing**

To measure glucose metabolism, a semi-quantitative ratio index of $^{[18F]}$FDG was calculated as standardized uptake value (SUV) ratio, where the SUV represents tracer activity per injected dose normalized to body weight. The SUV of each region was divided by the SUV of the whole brain as the global mean in each participant, and expressed as the SUV ratio (SUVR) image.

The non-displaceable binding potential (BP$_{ND}$) of $^{[11C]}$DPA-713 was estimated with the simplified reference tissue model using the PMOD 3.4 software (PMOD Technologies Ltd., Zurich, Switzerland) based on supervised cluster analysis, as described previously [22]. In short, we first generated a normalized input curve by averaging the time activity curves (TAC) from areal ROIs placed over the bilateral frontal, temporal, parietal, and occipital cortices; thalamus; putamen; caudate; cerebellar hemisphere; and brain stem. Then, this normalized mean TAC adjusted to the TAC with lowest PET counts from the cerebral cortical regions in each participant was used as the TAC for the reference input curve of the patients and controls. The lowest TAC for each participant was determined using clustered analysis, in which small circular ROIs of 2 mm in diameter were placed fully within the ROIs already determined in the cerebral cortical and subcortical regions on MRI, and the TACs with the lowest peak from each TAC of all of the small ROIs was obtained. The extracerebral structures were then masked by demarcating the cerebral regions on the brain MRI. Finally, the $^{[11C]}$DPA713 BP$_{ND}$ was obtained for each region and expressed as the BP$_{ND}$ image.

**Statistical parametric mapping analysis**

To identify the regions of significantly decreased glucose metabolism and elevated neuroinflammation in the FSS group, the voxel-based analyses of the $^{[18F]}$FDG SUVR and $^{[11C]}$DPA713 BP$_{ND}$ image maps were analyzed using the Statistical Parametric Mapping 8 software (SPM8; Wellcome Department of Imaging Neurosciences, London, UK). All $^{[18F]}$FDG SUVR and $^{[11C]}$DPA713 BP$_{ND}$ images were first normalized to the Montreal Neurological Institute (MNI) 152 standard space provided by SPM8 used as a default template. The between-group comparisons (FSS group vs. FDG control group and FSS group vs. DPA control group) for each parameter were performed using family-wise error (FWE) multiple-comparisons correction, with the statistical threshold set at $p < 0.05$.

To investigate the change in regional brain volume between FSS and control (age-matched DPA control) groups, voxel-based morphometry (VBM) was performed using SPM8 with Diffuseomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) toolbox. T1-weighted images were segmented into gray matter, white matter, cerebrospinal fluid, skull, soft tissue, and air/background using the “New Segment” algorithm in SPM8. A customized template was created from the images of FSS and control groups. Modulated gray and white matter segments were normalized to Montreal Neurological Institute (MNI) 152 standard space default template provided by SPM8. Images were smoothed with 8-mm FWHM Gaussian kernel and two-sample $t$ tests throughout the whole brain were performed in SPM8. A voxel-level height threshold was set at $p < 0.05$ (FWE corrected).

**ROI analysis**

Regional $^{[18F]}$FDG SUVR and $^{[11C]}$DPA713 BP$_{ND}$ values were determined from ROIs located in 10 brain regions: the pons, midbrain, bilateral hippocampus, amygdala, thalamus, and anterior cingulate cortices on the individual MRI because a previous study had demonstrated the presence of neuroinflammation in these areas in patients with CFS, a type of FSS [18]. These ROIs were then automatically transferred onto corresponding $^{[18F]}$FDG SUVR and $^{[11C]}$DPA713 BP$_{ND}$ parametric images. Regional $^{[18F]}$FDG SUVR and $^{[11C]}$DPA713 BP$_{ND}$ values derived from these ROIs were determined using the PMOD software. We investigated the relationship
between the clinical scores and each of the above-mentioned regional $^{[18F]}$FDG SUVR and $^{[11C]}$DPA-713 BP$_{ND}$ values using Pearson’s correlation analysis and linear regression analysis because the normality was found for these clinical data. Statistical significance was set to $p < 0.005$ ($p < 0.05$ with Bonferroni’s correction). Furthermore, we focused on these regions to examine whether and where neuroinflammation was directly associated with glucose hypometabolism through correlations between $^{[18F]}$FDG SUVR and $^{[11C]}$DPA-713 BP$_{ND}$ values from each ROI in the FSS group using Pearson’s correlation analysis and linear regression analysis in the GraphPad Prism 5.0 package (GraphPad, San Diego, CA, USA). Statistical significance was set to $p < 0.005$ ($p < 0.05$ with Bonferroni’s correction).

### Results

#### Demographic and clinical characteristics of the study participants

The demographic and clinical characteristics, including the numerical rating scale for pain, the Chalder fatigue scale, Stanford sleepiness scale, WAIS-III, and WMS-R scores, are presented in Table 1. All groups were matched for sex. The mean ages of the DPA control group (mean age ± SD 20.6 ± 1.6) and the FSS group (19.3 ± 1.5 years) were not statistically different, but the FDG control group (32.8 ± 9.5 years) was significantly older than the FSS group. In the WMS-R test, there were some missing scores due to lack of persistence in some patients.

### SPM analysis: comparison of $^{[18F]}$FDG SUVR and $^{[11C]}$DPA-713 BP$_{ND}$ between the FSS and control groups

The results of SPM for $^{[18F]}$FDG SUVR in the FSS group compared with FDG control group are shown in Fig. 1. On three-dimensionally rendered images, statistically significant differences of $^{[18F]}$FDG SUVR were observed in the mesial temporal region, thalamus, circumventricular region, and tegmentum of the brainstem, bilaterally (Fig. 1a, Table 2a). Although there was an age difference between the FSS and FDG control groups, this finding indicated that the brain regions with

---

**Table 1** Demographic and clinical characteristics of the study participants

| Characteristics                  | FSS group (n = 12) | Control group $^{[18F]}$FDG PET (n = 12) | $^{[11C]}$DPA713 PET (n = 16) |
|----------------------------------|--------------------|----------------------------------------|-----------------------------|
| Age (years)                      | 19.3 ± 1.5         | 32.8 ± 9.5*                             | 20.6 ± 1.6                  |
| Women/men                        | 12/0               | 12/0                                    | 16/0                        |
| Disease duration (years)         | 43 ± 0.7           | n.a.                                    | n.a.                        |
| Clinical scores (score range)    | n.a.               | n.a.                                    | n.a.                        |
| Numerical rating scale (0 - 10)a | 4.0 ± 1.8          | n.a.                                    | n.a.                        |
| Chalder fatigue scale (1 - 33)b  | 21.4 ± 7.5         | n.a.                                    | n.a.                        |
| Stanford sleepiness scale (1 - 7)c| 3.4 ± 1.4          | n.a.                                    | n.a.                        |
| WAIS-IIId                        |                    |                                        |                             |
| Full-scale IQ                    | 80.6 ± 11.6        | n.a.                                    | n.a.                        |
| Verbal IQ                        | 81.8 ± 8.6         | n.a.                                    | n.a.                        |
| Performance IQ                   | 83.7 ± 16.8        | n.a.                                    | n.a.                        |
| Verbal comprehension             | 86.7 ± 9.3         | n.a.                                    | n.a.                        |
| Perceptual organization          | 83.6 ± 16.4        | n.a.                                    | n.a.                        |
| Working memory                   | 79.6 ± 14.2        | n.a.                                    | n.a.                        |
| Processing speed                 | 80.4 ± 18.4        | n.a.                                    | n.a.                        |
| WMS-Rd                           |                    |                                        |                             |
| Full memory                      | 86.1 ± 16.6        | n.a.                                    | n.a.                        |
| Verbal memory                    | 85.7 ± 19.2        | n.a.                                    | n.a.                        |
| Visual memory                    | 87.9 ± 16.2        | n.a.                                    | n.a.                        |
| Attention memory                 | 77.3 ± 15.2        | n.a.                                    | n.a.                        |
| Delayed memory                   | 74.7 ± 20.6        | n.a.                                    | n.a.                        |

Data are the mean ± standard deviation (SD) or the number
IQ: intelligence quotient, n.a: not available, WAIS-III: Wechsler Adult Intelligence Scale-Third Edition, WMS-R: Wechsler Memory Scale-Revised
*aP < 0.05
*bPain scale ranges from 0 (no pain) to 10 (worst pain)
*cFatigue scale with higher scores indicating a greater degree of fatigue
*dSleep scale ranges from 1 (wide awake) to 7 (no longer fighting sleep)
*The average IQ and memory score is defined as 100 and the SD as 15 (i.e., approximately two-thirds of all scores between 85 and 115)
Fig. 1 Voxel-wise analysis of [18F]FDG standardized uptake value ratio images (p < 0.05, family-wise error corrected). Regions with a significant reduction of [18F]FDG standardized uptake value ratio (SUVR) are highlighted on three-dimensionally rendered brain-surface images (a). Axial (b), coronal (c), and sagittal (d) magnetic resonance images show the regions with a significant reduction of [18F]FDG SUVR (p < 0.05, family-wise error corrected). The color bar denotes the T value (0–8). R, right.

Table 2 Statistical parametric mapping results for [18F]FDG SUVR and [11C]DPA-713 BPND

| Anatomical region | BA | Talairach coordinate (x,y,z) | Cluster size | Voxel T size | Z score | Cluster p value | FWE | FDR | Uncorrected |
|-------------------|----|-----------------------------|--------------|--------------|---------|----------------|-----|-----|------------|
| a: [18F]FDG SUVR (FSS group vs. [18F]FDG PET control group) | | | | | | | | | | |
| R uncus | 36 | 31.7 | −1.4 | −28.5 | 257 | 8.01 | 5.43 | < 0.001 | < 0.001 | < 0.001 |
| R hippocampus | 31.7 | −8.7 | −19.7 | 7.28 | 5.14 |
| R parahippocampus | 34 | 17.8 | −0.8 | −15.1 | 6.76 | 4.92 |
| L thalamus | −9.9 | −29.3 | −3.6 | 356 | 6.70 | 4.90 | < 0.001 | < 0.001 | < 0.001 |
| L hippocampus | −33.7 | −31.4 | −6.8 | 197 | 6.93 | 5.0 | < 0.001 | < 0.001 | < 0.001 |
| L insula | 13 | −41.6 | −31.9 | 21.9 | 6.80 | 4.94 | 0.019 | 0.473 | 0.368 |
| L anterior cingulate | 25 | 0 | −0.34 | −6.7 | 6.75 | 4.92 | < 0.001 | 0.001 | 0.001 |
| L uncus | 28 | −21.8 | 2.5 | −27.0 | 3 | 6.16 | 4.65 | 0.029 | 0.566 | 0.566 |
| b: [11C]DPA-713 BPND (FSS group vs. [11C]DPA713 PET control group) | | | | | | | | | | |
| L thalamus | −4.0 | −27.2 | −2.0 | 4560 | 10.18 | 6.41 | < 0.001 | < 0.001 | < 0.001 |
| L amygdala | −25.7 | −1.2 | −23.5 | 208 | 7.78 | 5.54 | < 0.001 | < 0.001 | < 0.001 |
| L hippocampus | −25.7 | −14.2 | −11.1 | 7.30 | 5.34 |
| L parahippocampus | 34 | −17.8 | −6.7 | −18.2 | 5.72 | 5.07 |
| R inferior temporal gyrus | 20 | 55.4 | −13.1 | −29.6 | 58 | 7.35 | 5.36 | < 0.001 | 0.034 | 0.009 |
| R middle temporal gyrus | 20 | 55.4 | −39.6 | −29.6 | 61 | 7.22 | 5.30 | < 0.001 | 0.034 | 0.008 |
| R fusiform gyrus | 20 | 55.4 | −34.0 | −20.2 | 6.90 | 5.15 |
| R middle temporal gyrus | 21 | 49.5 | −4.5 | −25.5 | 144 | 7.11 | 5.25 | < 0.001 | 0.001 | < 0.001 |
| L superior temporal gyrus | 38 | −37.6 | 12.2 | −27.5 | 31 | 6.79 | 5.10 | 0.002 | 0.12 | 0.047 |
| L fusiform gyrus | 20 | −55.4 | −16.6 | −21.0 | 22 | 6.71 | 5.07 | 0.004 | 0.182 | 0.087 |
| L superior frontal gyrus | 6 | −5.9 | 8.9 | 62.2 | 20 | 6.49 | 4.96 | 0.005 | 0.182 | 0.101 |
| L middle frontal gyrus | 11 | −27.7 | 34.4 | −11.8 | 21 | 6.46 | 4.95 | 0.005 | 0.182 | 0.094 |
| R uncus | 30 | 41.6 | −26.2 | 19.7 | 12 | 6.16 | 4.80 | 0.010 | 0.321 | 0.196 |

SUVR standardized uptake value ratio, BPND binding potential, BA Brodmann’s area, L left, R right, FWE family-wise error, FDR false discovery rate
reduced cerebral glucose metabolism were mostly confined to the thalamo-limbic-tegmental brainstem system in FSS.

The results of SPM for $[^{11}C]$DPA713 BP$_{ND}$ in the FSS group compared with DPA control group are shown in Fig. 2. On three-dimensionally rendered images, a significant increase of $[^{11}C]$DPA713 BP$_{ND}$ levels was observed in the mesial temporal and inferior frontal cortices, thalamus, and tegmentum of the brainstem (Fig. 2a, Table 2b). The results of SPM on reduced $[^{18}F]$FDG SUVR and increased $[^{11}C]$DPA713 BP$_{ND}$ were similar in various brain regions in the FSS group, suggesting that glucose hypometabolism occurred concomitantly with neuroinflammation in key brain regions, i.e., the thalamo-limbic-brainstem region.

The VBM analysis using SPM showed no significant difference in regional brain volume between the FSS and control groups (data not shown).

ROI analyses

(i) Direct relationship between $[^{18}F]$FDG SUVR and $[^{11}C]$DPA713 BP$_{ND}$

Direct comparisons between $[^{18}F]$FDG SUVR and $[^{11}C]$DPA713 BP$_{ND}$ in the same ROIs showed significantly positive correlations in the right hippocampus ($R^2 = 0.597, p = 0.003$) and right amygdala ($R^2 = 0.556, p = 0.002$) (Fig. 3a, b). There was no significant correlation in the anterior cingulate cortices and thalamus (Fig. 3c, d).

(ii) Correlations of clinical scores with $[^{18}F]$FDG SUVR or $[^{11}C]$DPA713 BP$_{ND}$

Pearson’s correlation analysis revealed significantly positive correlations between the levels of $[^{18}F]$FDG SUVR in the left thalamus ($r = 0.81, p < 0.05$ corrected) and working memory in WAIS-III, and between the levels of $[^{18}F]$FDG SUVR in the left hippocampus ($r = 0.80, p < 0.05$ corrected) and right thalamus ($r = 0.84, p < 0.05$ corrected) and processing speed performance in WAIS-III in the FSS group (Table 3a). Regarding the clinical relevance on $[^{11}C]$DPA713 BP$_{ND}$, Pearson’s correlation analysis revealed significantly negative correlations between $[^{11}C]$DPA713 BP$_{ND}$ levels in the left hippocampus ($r = -0.77, p < 0.05$ corrected), right thalamus ($r = -0.79, p < 0.05$ corrected), and pons ($r = -0.81, p < 0.05$ corrected) and verbal comprehension in WAIS-III, and between $[^{11}C]$DPA713 BP$_{ND}$ levels in the right thalamus and verbal memory in WMS-R ($r = -0.85, p < 0.05$, corrected) (Table 3b).

Discussion

To the best of our knowledge, this is the first study to clarify the concurrent changes in cerebral glucose hypometabolism and neuroinflammation in patients with FSS. In this study, we showed that young women with FSS had significantly decreased $[^{18}F]$FDG SUVR and increased $[^{11}C]$DPA-713 BP$_{ND}$ in unique brain regions covering the thalamus, mesial temporal region, and tegmentum of the brainstem. We also showed that $[^{18}F]$FDG SUVR and $[^{11}C]$DPA-713 BP$_{ND}$ values in these regions were associated with clinical scores in WAIS-III and WMS-R tests. Thus, cerebral glucose hypometabolism and elevated neuroinflammatory responses in the confined brain regions together with their clinical relevance reflect the pathophysiology of FSS.
Cerebral glucose metabolism is related to the cerebral blood flow (CBF) [23], and CBF measurement by single-photon emission computed tomography (SPECT) might suggest the pathological mechanism of FSS. Indeed, our previous study using 123IMP-SPECT in patients with various symptoms following HPV vaccination showed significant reduction in CBF in the regions associated with the right limbic system [24]. Our present study identified unique brain regions with glucose hypometabolism, some of which matched the regions with decreased CBF, namely the mesial temporal region and the thalamus [24].

Several other PET studies have reported changes in cerebral glucose metabolism in FSS spectrum disorders. Patients with CFS manifest a significant reduction in cerebral glucose metabolism in the medial–frontal cortex and brainstem [16] or a small reduction nonspecifically in the brain [25]. In patients with fibromyalgia, an elevation of glucose metabolism in the limbic system is observed post-treatment [17]. A series of studies on glucose metabolism in these FSS spectrum disorders indicated that the limbic region might be a core region for the development of FSS symptoms.

This one-stop measurement of glucose metabolism may be used to estimate the steady-state level of cerebral function. Combining metabolic steady-state and inflammatory state measurements could allow additional information on the brain milieu. Beside the limbic system, we
detected significant glucose hypometabolism in the dorsal part of the brainstem and thalamus. As discussed below, the current cerebral hypometabolism regions in FSS might be linked with increased neuroinflammation because of co-occurrence with the decreased $^{[18F]}$FDG and increased $^{[11C]}$DPA713, suggesting that glucose hypometabolism could be associated with neuroinflammation. At least in the current study, brain volume was not responsible for this hypometabolism because a VBM analysis showed no difference between FSS and age-matched control groups. Thus, cerebral glucose hypometabolism in these regions might be pathophysiologically implicated.

PET imaging of TSPO is widely used to monitor neuroinflammation in neurological and psychiatric disorders [9, 12]. A recent PET study revealed significantly higher $^{[11C]}$(R)-PK11195 BP$_{ND}$ in patients with chronic fatigue syndrome than in healthy controls in the thalamus, midbrain, and pons [18]. The pattern of high $^{[11C]}$(R)-PK11195 BP$_{ND}$ in these regions is consistent with our findings. Moreover, in our study using $^{[11C]}$DPA713, which is more specific than $^{[11C]}$(R)-PK11195 [22], increased $^{[11C]}$DPA713 binding was found in broader regions covering the mesial temporal region, thalamus, and brainstem in FSS.

One possible explanation for the presence of neuroinflammation may be related to the inflammatory cytokines in circulation. One review about patients with CFS described that circulating cytokines, such as tumor necrosis factor-α, interferon-γ, interleukin (IL)-6, and IL-1, are associated with the initiation of inflammation [26].

Table 3: Correlation between $^{[18F]}$FDG SUVR or $^{[11C]}$DPA713 BP$_{ND}$ values and clinical scores

| Clinical score | Anatomical region | Side | Correlation coefficient (r) | p value |
|---------------|-------------------|------|-----------------------------|---------|
| a: $^{[18F]}$FDG SUVR | | | | |
| WAIS-III | | | | |
| Working memory | Hippocampus | R | 0.65 | 0.022 |
| Thalamus | R | 0.64 | 0.025 |
| Thalamus | L | 0.81 | 0.002* |
| Processing speed | Hippocampus | R | 0.64 | 0.026 |
| Hippocampus | L | 0.80 | 0.002* |
| Amygdala | R | 0.61 | 0.034 |
| Thalamus | R | 0.84 | < 0.001* |
| Thalamus | L | 0.67 | 0.017 |
| WMS-R | | | | |
| Attention memory | Hippocampus | R | 0.70 | 0.024 |
| b: $^{[11C]}$DPA713 BP$_{ND}$ | | | | |
| WAIS-III | Verbal comprehension | Hippocampus | L | −0.77 | 0.003* |
| Amygdala | L | −0.62 | 0.031 |
| Anterior cingulate | R | −0.71 | 0.009 |
| anterior cingulate | L | −0.74 | 0.006 |
| Thalamus | R | −0.79 | 0.002* |
| Thalamus | L | −0.75 | 0.005 |
| Pons | | | | |
| Midbrain | | | | |
| WMS-R | Verbal memory | Hippocampus | L | −0.67 | 0.024 |
| Amygdala | L | −0.70 | 0.017 |
| Anterior cingulate | L | −0.66 | 0.027 |
| Thalamus | R | −0.85 | < 0.001* |
| Thalamus | L | −0.69 | 0.018 |
| Pons | | | | |

SUVR standardized uptake value ratio, BP$_{ND}$ binding potential, L left, R right, WAIS-III Wechsler Adult Intelligence Scale-Third Edition, WMS-R Wechsler Memory Scale-Revised

*p < 0.05 with Bonferroni’s correction
Patients with fibromyalgia were reported to show higher serum levels of IL-1 receptor antagonist, IL-6, and IL-8 [27]. Hence, inflammatory cytokines may affect the brain regions described above due to cytokine infiltration. Another possible mechanism of neuroinflammation may be stress-induced neuronal deactivation. Indeed, stress sensitizes peripheral as well as central cytokine responses, leading to neuroinflammation and hypothalamic–pituitary–adrenal axis activation [28]. Endogenous cytokine expression and associated cytokine receptor responses are found throughout the brain, including the circumventricular thalamic regions, brainstem nuclei, hypothalamus, and basal ganglia [28]. In any possibility, neuroinflammation in the unique brain regions is an underlying phenomenon responsible for FSS symptoms.

We found unique brain regions with cerebral glucose hypometabolism and neuroinflammation that were associated with key clinical features in patients with FSS. Significant correlations of psycho-behavioral scores with levels of $[^{18}F]$FDG SUVR and $[^{11}C]$DPA713 BPND were found mainly in the thalamus and hippocampus (Table 3). Although there was a right–left lateralization in regions with significance, the levels of $[^{18}F]$FDG SUVR and $[^{11}C]$DPA713 BPND in the thalamus and hippocampus on both sides correlated considerably well with psycho-behavioral scores (Table 3). This suggested that the currently observed lateralization is not essential in the clinico-bioindex relevance. It is known that the thalamus is important in working memory and processing speed [29], acting as a central monitor for language processing and cortical activity [30, 31]. The circumventricular regions that were highlighted in the present study are associated with neuroendocrine regulation, stress response, immunomodulation, and cognitive regulation [32]. The hippocampus is also associated with language comprehension and processing speed [33, 34]. In the brainstem, the dorsal part, including the locus coeruleus and raphe nucleus, were highlighted in the present study. These nuclei are origins of the noradrenergic and serotonergic systems, subserving autonomic and emotional control, respectively. Taken together, the neuroinflammation-induced cerebral glucose hypometabolism in these peculiar regions may lead to the development of FSS symptoms.

Interestingly, our direct comparison between $[^{18}F]$FDG SUVR and $[^{11}C]$DPA713 BPND showed a positive correlation in the right hippocampus and amygdala. Since it was reported that TSPO-based PET findings in chronic, but not early, brain disease reflect a proinflammatory state [35, 36], it seems theoretically possible that lower cerebral metabolism couples with higher proinflammatory responses, i.e., $[^{18}F]$FDG SUVR could negatively correlate with $[^{11}C]$DPA713 BPND. Our present result contradicts this hypothesis. Because $[^{18}F]$FDG measurement does not differentiate anaerobic glycolysis, which is predominant in microglia [37], from aerobic glycolysis, the current result suggested that the higher $[^{18}F]$FDG uptake accompanied greater glycolysis in the hippocampus and amygdala, which subserve memory and emotion in patients with FSS. In the present study, a significant reduction in glucose metabolism was found in patients with FSS compared with healthy subjects. Hence, one possible interpretation is that the true amount of glucose metabolism in neurons might be much lower than the observable level that contained glial glucose consumption. One solution may be the use of a new PET tracer for oxidative metabolism in mitochondria. Oxidative metabolism is higher in neurons than in glial cells. Therefore, the new PET tracer could be used to distinguish the neuron-dominant glucose metabolism from neuroinflammation-related glucose consumption [38].

The present study has several limitations. First, the etiology of FSS is unknown. The patients in the current study developed FSS symptoms after different time intervals following HPV vaccination. HPV vaccination might contribute partly to FSS: HPV-treated mice manifest altered behavioral responses and microglial activation in the hippocampus CA1 area [39]. However, our results showing a greater extent of neuroinflammation outside the hippocampus and the development of FSS symptoms irrespective of vaccination [40] suggest that HPV vaccination may not be involved in the development of FSS, rather a need to prepare for development of FSS if one has altered metabolism or neuroinflammation in the thalamo-limbo-brainstem region in the brain. Second, the rs6971 polymorphism poses an issue for second-generation TSPO tracers such as $[^{11}C]$DPA713 [41]. As most Asian people are moderate affinity binders with moderately homogenous pattern of polymorphism [41], our findings in Japanese women may not have been affected by the polymorphism. Third, there was a significant age difference in the $[^{18}F]$FDG study between patients and controls (patients were younger than controls). While there was no significant change in brain volume in the current study from prior data of younger individuals, the previous study indicated that cerebral glucose metabolism is subject to age-related changes, especially in the dorsolateral prefrontal, inferior temporal/fusiform, and primary somatosensory cortices [42, 43]. This suggests that lower glucose metabolism found in the FSS group would have been more remarkable if a strictly age-matched control group was used. Fourth, our sample size was relatively small. Despite this limitation, we were able to show significant differences among groups under a rigorous statistical level.

Conclusions

Our results show that both cerebral glucose hypometabolism and neuroinflammation were concurrently...
present in unique brain areas covering the thalamolimbio-brainstem region in patients with FSS. A close relationship of cognitive impairment with metabolic and inflammatory abnormality in these regions provides better understanding of the clinicopathophysiology of FSS.

Abbreviations
AC–PC: Anterior commissure–posterior commissure; BP NDI: Binding potential; CBF: Cerebral blood flow; CFS: Chronic fatigue syndrome; FSS: Functional somatic syndromes; FWE: Family-wise error; HPV: Human papillomavirus; IL: Interleukin; MINI: Montreal Neurological Institute; MRI: Magnetic resonance imaging; PET: Positron emission tomography; ROI: Region of interest; SD: Standard deviation; SPECT: Single-photon emission computed tomography; SPM: Statistical parametric mapping; SUVR: Standardized uptake value ratio; TAC: Time activity curves; TSPO: Translocator protein; VBM: Voxel-based morphometry; WAIS-III: Wechsler Adult Intelligence Scale–Third Edition; WMS-R: Wechsler Memory Scale–Revised

Acknowledgements
We thank Messer, Toshihiko Kanno, Ichiro Ando, Shigeru Ito, and the staff of the Hamamatsu Medical Center and Hamamatsu PET Imaging Center for their valuable assistance.

Author contributions
Conceptualization and design: T.M., T.T., Y.O.; Methodology: T.M., T.T., T.O., Y.T., M.Y., Y.O.; Formal analysis and investigation: T.M., T.T., Y.O.; Writing–original draft preparation: T.M., T.T.; All co-authors provided critical revisions of the manuscript for important intellectual content. The authors read and approved the final manuscript.

Funding
This study was supported by the grants from Japan Society for the Promotion of Science KAKENHI (17H04247001) and Scientific Research on Innovative Areas (JP16H06402A01:WILLDYNAMICS).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was reviewed and approved by the Ethics Committee of the Hamamatsu Medical Center and Hamamatsu PET Imaging Center. Written informed consent was obtained from all patients or their guardians included in the study.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interest.

Author details
1Department of Biofunctional Imaging, Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan. 2Department of Neurology, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO, National Epilepsy Center, Shizuoka, Japan. 3Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan. 4Department of Pediatrics, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO, National Epilepsy Center, Shizuoka, Japan.

Received: 27 November 2019 Accepted: 12 March 2020
Published online: 20 March 2020

References
1. Henningen P, Zippel S, Herzog W. Management of functional somatic syndromes. Lancet. 2007;369:946–55.
2. Wesely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet. 1999;354:936–9.
3. Kinoshita T, Abe RT, Hineno A, Tsunezuka K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53:2185–200.
4. Brinth L, Theibel AC, Pors K, Mehlisen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J. 2015;62(4):A5064.
5. https://www.mhlw.go.jp/stf/shingi2/0000190696.html.
6. Catani M, Dell’Acqua F, Thiebaut de Schotten M. A revised limbic system model for memory, emotion and behaviour. Neurosci Biobehav Rev. 2013; 37:1724–37.
7. Berti V, Moisoni L, Pupi A. Brain: normal variations and benign findings in [11C]diprenorphine PET imaging. Eur J Nucl Med Mol Imaging. 2014;41:129–40.
8. Barani RB. Visualising microglial activation in vivo. Glia. 2002;40:206–17.
9. Dupont AC, Landau B, Santiago Ribeiro MU, Guilloteau Trotel C, Afflitti N. Translocator protein–18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017; https://doi.org/10.3390/ijms18040785.
10. Llivisse S, Guellermier M, Héard AS, Petit F, Delahaye M, Van Camp N, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32:10809–18.
11. Chechneva OV, Deng W. Mitochondrial translocator protein (TSPO), astrocytes and neuroinflammation. Neural Regen Res. 2016;11:1056–7.
12. Hellwig S, Domshche K. Update on PET imaging biomarkers in the diagnosis of neuropsychiatric disorders. Curr Opin Neurol. 2019;32:539–47.
13. Pukhalsky AL, Shmarina GV, Alisokin VA, Sabelnikov A. HPA axis exhaustion and regulatory T cell accumulation in patients with a functional somatic syndrome: recent view on the problem of Gulf War veterans. J Neuroimmunum. 2008;196:133–8.
14. Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nat Rev Rheumatol. 2015;11:639–48.
15. Natelson BH, Weaver SA, Tsong CL, Ottenweller JE. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol. 2005; 12:52–5.
16. Torelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, et al. Brain–positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med. 1998;105:545–8.
17. Wallitt B, Roebbuck-Spencer T, Espósito G, Atkin F, Bleiberg I, Fodor G, et al. The effects of multidisciplinary therapy on positron emission tomography in the brain of fibromyalgia: a pilot study. Rheumatol Int. 2007;27:1019–24.
18. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an [11C]–([R])PK11195 PET study. J Nucl Med. 2014;55:945–50.
19. Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993;55:195–203.
20. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wesely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147–57.
21. Heddle E, Dement W, Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology. 1972;9:150.
22. Yokokura M, Terada T, Buni T, Nakaiami K, Takabayashi K, Iwata Y, et al. Depiction of microglial activation in aging and dementia: positron emission tomography with [11C]P173713 versus [11C]PK11195. J Cereb Blood Flow Metab. 2017;37:877–89.
23. Olaf B Paulson, Steen G Hasselbalch, Egill Rostrup, Gitte Moos Knudsen, and Dale Pallinir. Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab. 2010;30:12–14.
24. Matsuda T, Takahashi Y, Matuda K, Ikeda H, Utsu K, Obi T, et al. Cognitive dysfunction and regional cerebral blood flow changes in Japanese females after human papillomavirus vaccination. Neuror Clin Neurosci. 2016;2:220–7.
25. Sassenmeier T, Nik WA, Hardt J, Schreckenberger M, Egle UT, Bartenstein P. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003;74:922–8.
26. Yang T, Yang Y, Wang D, Li C, Qu Y, Guo J, et al. The clinical value of cytokines in chronic fatigue syndrome. J Transl Med. 2019;17:213.
27. Učeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12:245.
28. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am. 2009;29:247–64.
29. Fama R, Sullivan EV. Thalamic structures and associated cognitive functions: relations with age and aging. Neurosci Biobehav Rev. 2015;54:29–37.
30. Klostermann F, Krugel LK, Ehlen F. Functional roles of the thalamus for language capacities. Front Syst Neurosci. 2013;7:32.
31. Crosson B. Thalamic mechanisms in language: a reconsideration based on recent findings and concepts. Brain Lang. 2013;126:73–88.
32. Benarroch EE. Circumventricular organs: receptive and homeostatic functions and clinical implications. Neurology. 2011;77:1198–204.
33. O’Shea A, Cohen RA, Porges EC, Nissim NR, Woods AJ. Cognitive aging and the hippocampus in older adults. Front Aging Neurosci. 2016;8:298.
34. Piai V, Anderson KL, Lin JJ, Dewar C, Parvial J, Drorke NF, Knight RT. Direct brain recordings reveal hippocampal rhythm underpinnings of language processing. Proc Natl Acad Sci U S A. 2016;113:11366–71.
35. Hosoya T, Fukumoto D, Kakiuchi T, Nishiyama S, Yamamoto S, Ohba H, et al. In vivo TSPO and cannabinoid receptor type 2 availability early in post-stroke neuroinflammation in rats: a positron emission tomography study. J Neuroinflammation. 2017;14:69.
36. Narayanawami V, Doll K, Bernard-Gauthier V, Josephson L, Cumming P, Vadenv N. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol Imaging. 2018;17:53011218792317.
37. Tsukada H, Nishiyama S, Fukumoto D, Kanazawa M, Harada N. Novel PET probes 18F-BCPP-EF and 18F-BCPP-BF for mitochondrial complex I: a PET study in comparison with 18F-BMS-747158-02 in rat brain. J Nucl Med. 2014;55:73–80.
38. Harada N, Nishiyama S, Kanazawa M, Tsukada H. Development of novel PET probes, [18F]BCPP-EF, [18F]BCPP-BF, and [11C]BCPP-EM for mitochondrial complex 1 imaging in the living brain. J Labelled Comp Radiopharm. 2013;56:53–61.
39. Inbar R, Weiss R, Tomljenovic L, Arango MT, Deri Y, Shaw CA, et al. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017;65:136–49.
40. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res. 2018:5:96–103.
41. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5.
42. Van Der Gucht A, Verger A, Guedj E, Malandain G, Hossu G, Yagdigul Y, et al. Age-related changes in FDG brain uptake are more accurately assessed when applying an adaptive template to the SPM method of voxel-based quantitative analysis. Ann Nucl Med. 2015;29:21–8.
43. Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.